A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Zacks.com on MSN

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Market voices: Lilly's new obesity drug, Bessent, EQT's robotics move

Eli Lilly (LLY) said that a late-stage study showed its new injected medication retatrutide helped obese patients lose up to ...